| Sep 23 |
New Data at AFS 2024 Demonstrates the Strength of Castle Biosciences’ TissueCypher® Test in Independently Predicting Risk of Developing Esophageal Cancer, Guiding Risk-Aligned Management Decisions for Patients with Barrett’s Esophagus
|
| Sep 16 |
Castle Biosciences’ Chief Operating Officer Kristen Oelschlager Named Arizona Bioscience Leader of the Year
|
| Sep 11 |
DecisionDx®-Melanoma Can Identify Melanoma Patients with Low Risk of Sentinel Lymph Node Positivity Who May Safely Forego Biopsy Surgery, New Independent Study Affirms
|
| Sep 5 |
Insider Sale: COO Kristen Oelschlager Sells Shares of Castle Biosciences Inc (CSTL)
|
| Sep 5 |
Study Confirms the Ability of Castle Biosciences' DecisionDx®-SCC Test to Predict Likelihood of Benefit from Adjuvant Radiation Therapy in Patients with High-Risk Cutaneous Squamous Cell Carcinoma
|
| Aug 28 |
Castle Biosciences to Participate in Upcoming Investor Conferences
|
| Aug 16 |
Castle Biosciences: Inflection Into Profitability
|
| Aug 7 |
Castle Biosciences Second Quarter 2024 Earnings: Beats Expectations
|
| Aug 6 |
Castle Biosciences, Inc. (CSTL) Q2 2024 Earnings Call Transcript
|
| Aug 5 |
Castle Biosciences, Inc. (CSTL) Q2 Earnings and Revenues Beat Estimates
|
